Reata Pharmaceuticals
(NASDAQ) RETA
This security has been delisted. This page is retained for historical reference.
RETA News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowRETA Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-122%
Net Income Margin
-141%
Return on Equity
47%
Return on Capital
-59%
Return on Assets
-61%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$2.22M
Operating Income
$270.15M
EBITDA
$269.02M
Operating Cash Flow
$204.27M
Capital Expenditure
$3.27M
Free Cash Flow
$207.54M
Cash & ST Invst.
$387.51M
Total Debt
$119.46M
Reata Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$22.75M
+2885.0%
Gross Profit
$21.90M
+2774.0%
Gross Margin
96.28%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
321
N/A
Net Income
$193.00M
+362.4%
EBITDA
$193.29M
+406.8%
Quarterly Fundamentals
Net Cash
$164.21M
-50.4%
Accounts Receivable
$22.66M
N/A
Inventory
$2.94M
N/A
Long Term Debt
$90.42M
-36.6%
Short Term Debt
$2.46M
-70.1%
Return on Assets
-60.62%
N/A
Return on Invested Capital
-59.31%
N/A
Free Cash Flow
$70.20M
-36.6%
Operating Cash Flow
$69.93M
-42.4%